BIO is the most underrated narrative in crypto, funding biotech research on-chain with a real use case and real-world impact, and it is starting to wake up. x.com 

BIO should accelerate if participants in the PEPTAI sale pull 50–100x, drawing attention and capital back into the Bio Protocol ecosystem. More people would then accumulate BIO to stake or mint BioXP, which helps qualify for sale allocations, and liquidity would flow downstream into DeSci and biotech plays, lifting the whole sector. x.com 

Biotech is the next AI trade, as AI turns drug discovery from a 10-year guessing game into a data problem while investors still treat the sector like a casino. Tempus AI uses a large clinical dataset for AI diagnostics; Recursion maps over a trillion cells with Genentech and Sanofi as partners; CRISPR Therapeutics has catalysts before end-2026; Absci designs antibodies with generative AI and starts Phase 2; Schrödinger sells physics-plus-AI design software and posted a surprise profit. x.com  … Show more

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

AbCellera's excellent Phase 2 data validates AI-augmented antibody discovery and commercialization as the future of medicine. Any large pullback would be a chance to add. x.com  x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Wiley's sell-off is a gift: it is one of the most promising AI data players, trading under 2x sales while projecting 27% growth, yet the market dumped it on one flat quarter. Peer-reviewed journals carry some of the highest per-token value of any data, which should rise dramatically in a few years, so taking on leverage to acquire content is welcome. @Heady_Creek counters that the core business is declining and AI growth comes from acquisitions like Emerald. x.com  x.com 

Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more

Platforms and assets serving compliant token fundraising stand to benefit from the SEC's proposed Reg CA, which pairs light private-placement burdens with public reach and immediate liquidity. Coinbase, which runs Coinbase Token Sales, and Robinhood gain from users, wallets, chains and distribution; Circle from raises in USDC; Ethereum, Solana and Avalanche as leading chains; Hyperliquid and Uniswap as liquidity venues. It is only a proposal and may tighten; back the shovels, not the projects. … Show more